IRGC

Across TCGA pan-cancer cohorts, IRGC mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IRGC data layer compared with 17 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IRGC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IRGC expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC and PDAC are the cancer types where IRGC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	1.000	0.225	.010	33	view →
PDAC	OS	Quartile	II,III,IV	1.000	0.745	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IRGC–HNSC (DFS)

Open the HNSC breakdown →